Online citations, reference lists, and bibliographies.
← Back to Search

PEG-stearate Coated Solid Lipid Nanoparticles As Levothyroxine Carriers For Oral Administration

S. Kashanian, E. Rostami
Published 2014 · Materials Science

Cite This
Download PDF
Analyze on Scholarcy
Share
In this study, poly ethylene glycol 100 stearate (PEG 100-S) was used to prepare coated solid lipid nanoparticles with loading levothyroxine sodium (levo-loaded PEG 100-S-coated SLNs) by microemulsification technique. Evaluation of the release kinetic of prepared colloidal carriers was conducted. The particle size and zeta potential of levo-loaded PEG 100-S-coated SLNs have been measured to be 187.5 nm and −23.0 mV, respectively, using photon correlation spectroscopy (PCS). Drug entrapment efficiency (EE) was calculated to be 99 %. Differential scanning calorimetry indicated that the majority of drug loaded in PEG 100-S-coated SLNs were in amorphous state which could be considered desirable for drug delivery. The purpose of this study was to develop a new nanoparticle system, consisting lipid nanoparticles coated with PEG 100-S. The modification procedure led to a reduction in the zeta potential values, varying from −40.0 to −23.0 mV for the uncoated and PEG-coated SLNs, respectively. Stability results of the nanoparticles in gastric and intestinal media show that the low pH of the gastric medium is responsible for the critical aggregation and degradation of the uncoated lipid nanoparticles. PEG 100-S-coated SLNs were more stable due to their polymer coating layer which prevented aggregation of SLNs. Consequently, it is possible that the PEG surrounds the particles reducing the attachment of enzymes and further degradation of the triglyceride cores. Shape and surface morphology of particles were determined by transition electron microscopy and scanning electron microscopy that revealed spherical shape of nanoparticles. In vitro drug release of PEG 100-S-coated SLNs was characterized using diffusion cell which showed a controlled release for drug.
This paper references
10.1023/A:1016085108889
Gastrointestinal Uptake of Biodegradable Microparticles: Effect of Particle Size
M. P. Desai (2004)
10.1016/J.JCIS.2004.10.012
Design and characterization of a new drug nanocarrier made from solid-liquid lipid mixtures.
M. Garcia-Fuentes (2005)
10.1016/J.COLSURFB.2005.08.005
Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system.
F. Hu (2005)
10.1097/CAD.0b013e3283099e5c
9-Nitrocamptothecin polymeric nanoparticles: cytotoxicity and pharmacokinetic studies of lactone and total forms of drug in rats
S. Dadashzadeh (2008)
10.1089/0894268041457183
PEG-PLA nanoparticles as carriers for nasal vaccine delivery.
A. Vila (2004)
Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives
Melike Üner (2007)
10.1186/1476-511X-8-1
Effects of probiotic bacteria, isoflavones and simvastatin on lipid profile and atherosclerosis in cholesterol-fed rabbits: a randomized double-blind study
Daniela Cu Cavallini (2008)
10.1210/JC.2005-2400
Levothyroxine treatment reduces thyroid size in children and adolescents with chronic autoimmune thyroiditis.
J. Svensson (2006)
10.2147/IJN.S15278
Effective screen for amyloid β aggregation inhibitor using amyloid β-conjugated gold nanoparticles
Sun-ho Han (2010)
10.1208/s12249-009-9197-2
Diazepam-Loaded Solid Lipid Nanoparticles: Design and Characterization
G. Abdelbary (2009)
10.2147/IJN.S20849
New surface-modified solid lipid nanoparticles using N-glutaryl phosphatidylethanolamine as the outer shell
S. Kashanian (2011)
10.1016/j.ijpharm.2008.08.013
Investigation of the carbopol gel of solid lipid nanoparticles for the transdermal iontophoretic delivery of triamcinolone acetonide acetate.
Wenhui Liu (2008)
10.3923/IJP.2009.90.93
Solid lipid nanoparticles preparation and characterization.
Nagi A. Alhaj (2009)
SOLID LIPID NANOPARTICLES: A REVIEW
P. Ekambaram (2012)
10.1016/J.JCONREL.2005.12.015
Chitosan-PEG nanocapsules as new carriers for oral peptide delivery. Effect of chitosan pegylation degree.
C. Prego (2006)
SLN as a topical delivery system for Artemisia arborescens essential oil: In vitro antiviral activity and skin permeation study
F. Lai (2007)
Preparation and characterization of nystatin-loaded solid lipid nanoparticles for topical delivery
R Khalil (2013)
Oral insulin delivery by means of solid lipid nanoparticles
B. Sarmento (2007)
10.2147/IJN.S7603
Nanofunctionalized zirconia and barium sulfate particles as bone cement additives
Riaz Gillani (2010)
10.2217/nnm.10.140
Nanofabrication techniques for controlled drug-release devices.
L. Chen (2011)
10.1016/S0378-5173(00)00361-6
Studies on the cyclosporin A loaded stearic acid nanoparticles.
Q. Zhang (2000)
10.1016/S0378-5173(98)00282-8
Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles
C. Bocca (1998)
10.1016/S0927-7765(99)00156-3
'Stealth' corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption.
Gref (2000)
Review: in vitro drug release characterization models
G Singhvi (2011)
10.1111/J.1365-2125.2005.02433.X
Effects of grapefruit juice on the absorption of levothyroxine.
Jari J. Lilja (2005)
10.2147/IJN.S11586
Preparation and in vitro characterization of 9-nitrocamptothecin-loaded long circulating nanoparticles for delivery in cancer patients
K. Derakhshandeh (2010)
10.1016/j.ejps.2009.04.008
Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin.
Robhash Kusam Subedi (2009)
10.1016/J.COLSURFA.2007.11.011
Effect of poly(ethylene glycol) stearate on the phase behavior of monocaprate/Tween80/water system and characterization of poly(ethylene glycol) stearate-modified solid lipid nanoparticles
Xinwei Li (2008)
trointestinal uptake of biodegradable microparticles : effect of particle size
MP Desai (1996)
10.1016/S0928-0987(97)86243-4
Solid lipid nanoparticles (SLN) for controlled drug delivery
R. Mueller (1996)
10.1208/aapsj070105
Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate
V. Blakesley (2008)
PREPARATION AND CHARACTERIZATION OF NYSTATIN-LOADED SOLID LIPID NANOPARTICLES FOR TOPICAL DELIVERY
R. Khalil (2013)
10.1016/J.IJPHARM.2005.01.018
Investigation of lectin-modified insulin liposomes as carriers for oral administration.
N. Zhang (2005)
10.1002/JPS.10368
Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin.
R. Cavalli (2003)
10.1016/S0378-5173(02)00080-7
Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin.
R. Cavalli (2002)
10.1016/J.EJPS.2004.01.006
Multiple level C in vitro/in vivo correlation of dissolution profiles of two L-thyroxine tablets with pharmacokinetics data obtained from patients treated for hypothyroidism.
N. M. Volpato (2004)
10.2147/IJN.S34301
Modification of polyethylene glycol onto solid lipid nanoparticles encapsulating a novel chemotherapeutic agent (PK-L4) to enhance solubility for injection delivery
Yi-ping Fang (2012)
10.1016/J.EJPB.2006.09.004
Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: factorial design, characterization and release kinetics.
K. Derakhshandeh (2007)
10.1016/J.IJPHARM.2004.12.030
New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin.
M. Garcia-Fuentes (2005)
10.1016/S0168-3659(01)00486-2
Design of biodegradable particles for protein delivery.
A. Vila (2002)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
10.2217/nnm.09.99
The right idea at the right time and writing Renku with us at Nanomedicine.
C. Martin (2010)
10.1016/J.IJPHARM.2004.02.032
Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery.
E. Souto (2004)
10.1111/j.2042-7158.1994.tb03854.x
Calcitonin and Insulin in Isobutylcyanoacrylate Nanocapsules: Protection Against Proteases and Effect on Intestinal Absorption in Rats
P. J. Lowe (1994)
10.1016/S0927-7765(02)00053-X
Design of lipid nanoparticles for the oral delivery of hydrophilic macromolecules
M. Garcia-Fuentes (2003)
10.1016/S0168-3659(99)00007-3
Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain.
S. Yang (1999)
10.1016/0378-5173(82)90099-0
A simple HPLC method for the dissolution studies on levothyroxine sodium tablets
R. Rapaka (1982)
10.1134/S1061934813060075
A derivative UV spectrophotometric method for the determination of levothyroxine sodium in tablets
Anabella Gregorini (2013)
10.1016/j.jpba.2010.08.025
Development and application of a validated HPLC method for the analysis of dissolution samples of levothyroxine sodium drug products.
J. Collier (2011)
10.1016/S0142-9612(02)00316-2
Bioactive calcium phosphate invert glass-ceramic coating on beta-type Ti-29Nb-13Ta-4.6Zr alloy.
T. Kasuga (2003)
10.3390/molecules181113340
Preparation and Optimization of Triptolide-Loaded Solid Lipid Nanoparticles for Oral Delivery with Reduced Gastric Irritation
C. Zhang (2013)
10.1016/S1359-0286(02)00117-1
Biodegradable nanoparticles for drug delivery and targeting
M. Hans (2002)
Solid lipid nanoparticles for cancer therapy
Bispo de Jesus (2015)
10.1016/0168-3659(90)90013-J
Nanocapsules as carriers for oral peptide delivery
C. Damgé (1990)
10.1016/S0142-9612(03)00331-4
Physico-chemical stability of colloidal lipid particles.
B. Heurtault (2003)
10.1002/JPS.10129
Pharmacokinetics and tissue distribution of idarubicin-loaded solid lipid nanoparticles after duodenal administration to rats.
G. Zara (2002)
10.1016/J.EJPS.2005.02.008
A comparative study of the potential of solid triglyceride nanostructures coated with chitosan or poly(ethylene glycol) as carriers for oral calcitonin delivery.
M. Garcia-Fuentes (2005)
10.1023/A:1012029517394
The Oral Absorption of Micro- and Nanoparticulates: Neither Exceptional Nor Unusual
A. Florence (2004)
10.1016/j.ijpharm.2008.04.018
Stability indicating validated HPLC method for quantification of levothyroxine with eight degradation peaks in the presence of excipients.
R. Shah (2008)
Production of Solid Lipid Nanoparticles-Drug Loading and Release Mechanism
R. Parhi (2010)
10.18433/J3D59T
Kinetic analysis of drug release from nanoparticles.
M. Barzegar-Jalali (2008)
10.1186/1476-511X-8-6
Lipid nanoparticles for transdermal delivery of flurbiprofen: formulation, in vitro, ex vivo and in vivo studies
K. Bhaskar (2009)
10.1111/j.2042-7158.1990.tb07033.x
Nanoparticle Uptake by the Rat Gastrointestinal Mucosa: Quantitation and Particle Size Dependency
P. Jani (1990)
10.1016/J.IJPHARM.2007.03.009
Solid lipid nanoparticles loaded with insulin by sodium cholate-phosphatidylcholine-based mixed micelles: preparation and characterization.
J. Liu (2007)



This paper is referenced by
10.1016/j.jconrel.2017.04.038
Lipophilic peptide character - What oral barriers fear the most.
O. Zupančič (2017)
10.1021/acs.langmuir.6b02402
Influence of Lipid Core Material on Physicochemical Characteristics of an Ursolic Acid-Loaded Nanostructured Lipid Carrier: An Attempt To Enhance Anticancer Activity.
P. Nahak (2016)
10.3109/02652048.2015.1094532
Modification of solid lipid nanoparticles loaded with nebivolol hydrochloride for improvement of oral bioavailability in treatment of hypertension: polyethylene glycol versus chitosan oligosaccharide lactate
Neslihan Üstündağ-Okur (2016)
10.22159/IJAP.2018V10I2.24738
DEVELOPMENT AND CHARACTERIZATION OF INDOMETHACIN-LOADED MUCOADHESIVE NANOSTRUCTURED LIPID CARRIERS FOR TOPICAL OCULAR DELIVERY
Pattravee Niamprem (2018)
10.3109/03639045.2014.956111
Development of dry powder inhaler formulation loaded with alendronate solid lipid nanoparticles: solid-state characterization and aerosol dispersion performance
Jafar Ezzati Nazhad Dolatabadi (2015)
THERAPEUTIC POTENTIAL OF DOXORUBICIN LOADED POLY (D, L-LACTIC- CO-GLYCOLIC ACID) AGAINST p-DIMETHYLAMINOAZOBENZENE INDUCED LIVER CANCER
K. Lakshmi Priya (2016)
10.1186/s11671-015-1172-0
In Vivo Biodistribution and Toxicity of Highly Soluble PEG-Coated Boron Nitride in Mice
B. Liu (2015)
10.1039/C5MD00104H
PEGylated solid lipid nanoparticles: design, methotrexate loading and biological evaluation in animal models
Dipti Kakkar (2015)
10.3390/pharmaceutics12010058
Stability and Compatibility Studies of Levothyroxine Sodium in Solid Binary Systems—Instrumental Screening
Ionuț Ledeți (2020)
10.1080/21691401.2018.1516671
Development and characterization of folic acid-functionalized apoferritin as a delivery vehicle for epirubicin against MCF-7 breast cancer cells
Hasanain Gomhor J Alqaraghuli (2018)
10.1016/j.ejpb.2016.02.012
Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide.
L. Gonçalves (2016)
10.1007/978-3-030-06115-9_14
Successful Delivery of Zidovudine-Loaded Docosanol Nanostructured Lipid Carriers (Docosanol NLCs) into Rat Brain
Tapash Chakraborty (2019)
10.1007/978-981-10-5864-6_6
Surface Engineering: Incorporation of Bioactive Compound
Muhammad K Riaz (2017)
10.1016/j.addr.2016.04.001
Lipid-based nanocarriers for oral peptide delivery.
Zhigao Niu (2016)
10.1208/s12249-016-0675-z
Preparation and Optimization of Meropenem-Loaded Solid Lipid Nanoparticles: In Vitro Evaluation and Molecular Modeling
Ellen K. G. Mhango (2016)
10.1016/B978-0-323-42978-8.00012-7
Solid Lipid Nanoparticles in Drug Delivery
A. Deshpande (2017)
10.1016/J.CPLETT.2016.12.019
A targeted drug delivery system based on dopamine functionalized nano graphene oxide
Elham Masoudipour (2017)
Semantic Scholar Logo Some data provided by SemanticScholar